THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

April 01, 2024
Samsung Bioepis launches half-priced Soliris biosimilar

Samsung Bioepis, a biosimilar developer under Samsung Group, announced Monday that the company decided to launch its Soliris biosimilar Epysqli in Korea at a price nearly 50 percent cheaper than the original drug. Epysqli is a biosimilar referencing Soliris, a high-cost drug for the treatment of r...
April 01, 2024
Hanmi heirs may seek to repair with family first

The management conflict within the founding family of Hanmi Pharmaceutical Group ended, as the sons of founder Lim Sung-ki -- Lim Jong-yoon and Lim Jong-hoon -- secured a majority within Hanmi Science’s board at the general meeting of shareholders last week. However, there are still multiple hurdl...
April 01, 2024
Kolmar Korea makes R&D push for bigger footing globally

The global rise in popularity of K-beauty brands has brought attention to Kolmar Korea, a leading cosmetics original design manufacturer that has secured a whopping 70 percent market share in the sun care sector alone here. According to the company Sunday, its “Fitting SPF Boosting” technology h...
March 28, 2024
Hanmi-OCI merger called off

The expected merger between OCI Group and Hanmi Group has been called off after a general meeting of shareholders at Hanmi Science, the holding company of Korea's leading drug firm Hanmi Pharmaceutical, on Thursday. The management conflict within the founding family has also temporarily ended as L...
March 28, 2024
Korea’s CMO ramp-up lures biotech investors

South Korea’s growing biopharmaceutical production capacity is increasingly making the country an attractive investment destination for global life science companies, industry sources said Thursday. Since 2016, global pharmaceutical and biotech firms started building their research and developmen...
March 28, 2024
Trade ministry, US bio firm Thermo Fisher discuss investment

The trade ministry said Thursday it has discussed a possible investment opportunity in South Korea with a major US biotechnology firm, as the country aims to become a global manufacturing hub in the industry. Trade Minister Cheong In-kyo met Mark Smedley, a senior vice president of Thermo Fisher S...
March 25, 2024
SK bioscience devises new business strategy for post-pandemic era

SK bioscience, a pharmaceutical affiliate under South Korea's SK Group, on Monday unveiled its latest strategic initiative, aimed at preparing for possible pandemics in the future and expanding into emerging sectors in the post-COVID-19 era. The new strategy, dubbed SKBS 3.0 Reboot, focuses on bro...
March 21, 2024
Merck to invest 300m euros in new bioprocessing center in Korea

German pharmaceutical group Merck Life Science said Thursday the company will invest around 300 million euros ($326 million) to build a new bioprocessing complex in South Korea, its largest investment yet in the Asia-Pacific region. The new investment comes as the company renews its commitment to ...
March 21, 2024
SK Bioscience exports cell-cultured flu vaccines to Thailand

South Korean pharmaceuticals firm SK Bioscience said Thursday that it exported its cell-cultured flu vaccine, SKYCellflu, to Thailand, marking its first entry into a market with southern hemisphere requirements. The company shipped out approximately 440,000 doses of SKYCellflu to its Thai partner ...
March 21, 2024
SK bioscience exports influenza vaccine SKYCellflu to Thailand

SK bioscience, a pharmaceutical affiliate under South Korea's SK Group, said Thursday the company has exported its influenza vaccine to Thailand as part of efforts to expand its business presence in the southeast Asian market. The company has shipped around 440,000 doses of SKYCellflu, a cell-cult...
March 21, 2024
Global pharma Merck to build new bioprocessing production facility in S. Korea

Global pharmaceutical company Merck Life Science said Thursday it will invest some 430 billion won ($324 million) to build a new bioprocessing production facility in South Korea. The European bio firm plans to build a 43,000 square-meter center in Daejeon, about 140 kilometers south of Seoul, equi...
March 19, 2024
Drugmakers feeling pinch from doctors’ walkout

The ongoing tug-of-war between the South Korean government and medical professionals over the proposed increase in the number of medical students could have negative impacts on local drug companies’ revenues as well, industry sources said Tuesday. According to officials from local pharmaceutical ...
March 18, 2024
Celltrion's Zymfentra makes US debut

Korean biopharmaceuticals firm Celltrion announced Monday that its new autoimmune disease treatment Zymfentra has been launched in the US market. Zymfentra is a subcutaneous injection formulation of Celltrion's infliximab Remsima. In October last year, the US Food and Drug Administration approved ...
March 18, 2024
Celltrion's new autoimmune disease treatment Zymfentra hits US market

South Korean biopharmaceutical firm Celltrion said Monday its new autoimmune disease treatment, Zymfentra, has made a debut in the US market. Zymfentra, a subcutaneous injection formulation of Celltrion's infliximab Remsima, won approval from the US Food and Drug Administration last year for use o...
March 18, 2024
Yuhan restores chairperson post after 28 years

South Korean pharmaceutical giant Yuhan has decided to reinstate the chairperson and vice chairperson positions for the first time in 28 years, since Chairman Yeon Man-hee stepped down from his post in 1996. Yuhan shareholders approved changes to the articles of incorporation to reestablish the po...

1 2 3 4 5

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099